Loading
TrAMPoline Pharma
TrAMPoline Pharma is developing MightyTIL, tumour-infiltrating immune cells taken from a patient's tumour and genetically strengthened before being returned, for sarcoma, head and neck cancer and melanoma. It is in laboratory testing.
Also called: Trampoline Pharma, Inc.TRAMPOLINE PHARMA, INC.
Overview
TrAMPoline Pharma develops autologous cellular immunotherapies for solid tumours. Its lead candidate MightyTIL is a gene-engineered tumour-infiltrating lymphocyte product using its coR8:Amp technology, which the company says enhances T cell receptor binding to cancer cells and T cell receptor signalling; it targets sarcoma, head and neck cancer and melanoma, and showed greater anti-tumour activity than unmodified TIL in animal models, according to the company. In fiscal year 2026 NCI awarded it USD 398,039 under SBIR award 1R43CA310292-01 for a universal T cell receptor therapy tested first against acute myeloid leukaemia.
Headquarters
Aurora, CO, US
Scorecard
All companies#803of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R43) 1R43CA310292-01: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization | 2026 | $398K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1PreclinicalGene-engineered tumour-infiltrating lymphocyte therapy
MightyTIL is an experimental cell treatment from TrAMPoline Pharma that strengthens immune cells taken from a patient's own tumour. It is in laboratory testing.
Notes
- Read on trampolinepharma.com and NIH RePORTER on 4 November 2026.
Connected
5Similar pages
- IdeaPublic cell-therapy foundries at cancer centres for academics and start-ups
Shares TIL therapy, TCR-T cell therapy.
- PersonPatrick Hwu
Shares TIL therapy, TCR-T cell therapy.
- PersonSteven A. Rosenberg
Shares TIL therapy, TCR-T cell therapy.
- IdeaHospital-exemption cell therapies at scale, backed by a shared registry
Shares TIL therapy, TCR-T cell therapy.
- TechnologyCell-therapy release and potency testing
Shares TIL therapy, TCR-T cell therapy.
- TechnologyCryopreservation and cell-therapy cold chain
Shares TIL therapy, TCR-T cell therapy.
- RoadmapCell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR
Shares TIL therapy, TCR-T cell therapy.
- InstitutionLausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Shares TIL therapy, TCR-T cell therapy.
fronts
technologies
drugs
PreclinicalGene-engineered tumour-infiltrating lymphocyte therapy
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
trampolinepharma.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/